DLL3 and neoplasm: Key factors include (1) Target Heterogeneity: Only 68% patients had high DLL3 expression (defined as ≥75% of tumor cells) (52), but the phase III TAHOE trial enrolled patients regardless of DLL3 levels (70), diluting efficacy.